Loading
PTX-912 is an experimental immune-stimulating protein from Proviva Therapeutics, in phase 1 trials for advanced solid tumours.
PTX-912 is a fusion protein (interleukin-2 prodrug) from Proviva Therapeutics. An interleukin-2 prodrug fusion protein meant to be switched on inside the tumour; Chinese financing reports describe it differently (one as immune-cell-targeted, one as a PD-1/IL-2 fusion), so no target is linked. The phase 1 study NCT06190886 is recruiting people with advanced solid tumours. Whether it works in people has not been established.
An interleukin-2 prodrug fusion protein meant to be switched on inside the tumour; Chinese financing reports describe it differently (one as immune-cell-targeted, one as a PD-1/IL-2 fusion), so no target is linked.
1.PTX-912 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PTX-912" OR ABSTRACT:"PTX-912") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTX-912, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/